Cel The clinical success of anticancer and antiviral vaccines often requires the use of an adjuvant, a substance that helps stimulate the body’s immune response to the vaccine, making it work better. However, few adjuvants are sufficiently potent and non-toxic for clinical use; moreover, it is not really known how they work. Current vaccine approaches based on weak carbohydrate and glycopeptide antigens are not being particularly effective to induce the human immune system to mount an effective fight against cancer. Despite intensive research and several clinical trials, no such carbohydrate-based antitumor vaccine has yet been approved for public use. In this context, the proposed project has a double, ultimate goal based on applying chemistry to address the above clear gaps in the adjuvant-vaccine field. First, I will develop new improved adjuvants and novel chemical strategies towards more effective, self-adjuvanting synthetic vaccines. Second, I will probe deeply into the molecular mechanisms of the synthetic constructs by combining extensive immunological evaluations with molecular target identification and detailed conformational studies. Thus, the singularity of this multidisciplinary proposal stems from the integration of its main objectives and approaches connecting chemical synthesis and chemical/structural biology with cellular and molecular immunology. This ground-breaking project at the chemistry-biology frontier will allow me to establish my own independent research group and explore key unresolved mechanistic questions in the adjuvant/vaccine arena with extraordinary chemical precision. Therefore, with this transformative and timely research program I aim to (a) develop novel synthetic antitumor and antiviral vaccines with improved properties and efficacy for their prospective translation into the clinic and (b) gain new critical insights into the molecular basis and three-dimensional structure underlying the biological activity of these constructs. Dziedzina nauki medical and health sciencesbasic medicineimmunologyimmunisationmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesnatural sciencesbiological sciencesbiochemistrybiomoleculescarbohydratesmedical and health sciencesclinical medicineoncologynatural sciencesbiological sciencesmolecular biologystructural biology Program(-y) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Temat(-y) ERC-2016-STG - ERC Starting Grant Zaproszenie do składania wniosków ERC-2016-STG Zobacz inne projekty w ramach tego zaproszenia System finansowania ERC-STG - Starting Grant Instytucja przyjmująca ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS Wkład UE netto € 1 499 218,75 Adres PARQUE TECNOLOGICO EDIFICIO 801 A 48160 Derio Vizcaya Hiszpania Zobacz na mapie Region Noreste País Vasco Bizkaia Rodzaj działalności Research Organisations Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 1 499 218,75 Beneficjenci (1) Sortuj alfabetycznie Sortuj według wkładu UE netto Rozwiń wszystko Zwiń wszystko ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS Hiszpania Wkład UE netto € 1 499 218,75 Adres PARQUE TECNOLOGICO EDIFICIO 801 A 48160 Derio Vizcaya Zobacz na mapie Region Noreste País Vasco Bizkaia Rodzaj działalności Research Organisations Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 1 499 218,75
